HOME

CONSOLIDATE. AUTOMATE. GROW.

The Panther® system consolidates a broad assay menu on a single, fully automated platform. With the Panther system, you can test for infectious pathogens and sexually transmitted infections (STIs) - including HIV-1, HCV, Zika virus*, chlamydia, gonorrhea, HPV and trichomoniasis - in parallel.

By activating the power of the Panther system, you'll see your workflow become flexible, streamlined and efficient. With no batching requirements and continuous access to samples and reagents, you can load, process and prioritize samples based on the needs of your lab. Release the full potential of the Panther system and watch your lab grow.

Aptima® assays now available for:

HIV-1 viral load
HCV viral load & confirmation
HBV viral load
CT/NG

Trich
HPV
HPV GT 16 18/45
HSV 1 & 2
Zika virus*

Additional Aptima assays in development for:

BV
CV
M. genitalium

See how Hologic is bringing its legacy of innovation to today’s world of molecular diagnostic testing.

Learn how real-time TMA leads to highly sensitive, highly specific assay performance.

CONTACT US

HOLOGIC

COUNTRIES

*The Aptima Zika Virus assay:

This test has not been FDA cleared or approved;
This test has been authorized by FDA under an EUA for use by authorized laboratories;
This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens; and
This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C.§ 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

©2018 Hologic, Inc. All rights reserved. Hologic, The Science of Sure, Aptima, Panther, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com

THE NEW STANDARD IN HIV-1 MOLECULAR TESTING

HCV HAS NOWHERE TO HIDE

Dual-Target HBV Treatment Management